Abstract
The 5-HT2C receptor (5-HT2CR) belongs to the family of seven transmembrane-containing G-protein-coupled receptors (GPCRs) and is located on the human X chromosome band q24. The pre-mRNA generated from this gene undergoes extensive RNA processing. Due to RNA editing and alternative splicing, the gene could generate at least 288 different isoforms. Under physiological conditions, the RNA processing is tightly regulated. Deviations from the normal processing patterns that disturb the balance between the mRNA isoforms lead to diseases. Here we describe the regulation of alternative splicing of exon Vb of the 5-HT2C receptor. This exon encodes the second intracellular loop that is important for signaling. The exon is regulated by a splicing silencer that can be modified by RNA editing. The inclusion of the nonedited exon Vb is promoted by a small nucleolar RNA (snoRNA), HBII-52/SNORD115 and its processed isoforms. The regulation of this exon appears to be altered in the Prader–Willi syndrome (PWS).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Biamonti G, Caceres JF (2009) Cellular stress and RNA splicing. Trends Biochem Sci 34:146–153.
Burns CM, Chu H, Rueter SM, et al (1997) Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 387:303–308.
Butler MG, Hanchett JM, Thompson TE (2006) Clinical Findings and Natural History of Prader-Willi Syndrome. In: Butler MG, Lee PDK, Whitman BY, eds. Management of Prader–Willi Syndrome. New York: Springer, pp. 3–48
Carrel AL, Lee PDK, Mogul HR (2006) Growth Hormone and Prader-Willi Syndrome. In: Butler MG, Lee PDK, Whitman BY, eds. Management of Prader-Willi Syndrome. New York: Springer, pp. 201–241
Cavaille J, Buiting K, Kiefmann M, et al (2000) Identification of brain-specific and imprinted small nucleolar RNA genes exhibiting an unusual genomic organization. Proc Natl Acad Sci USA 97:14311–14316.
Cummings DE, Clement K, Purnell JQ, et al (2002) Elevated plasma ghrelin levels in Prader–Willi syndrome. Nat Med 8:643–644.
de Lind van Wijngaarden RF, Otten BJ, Festen DA, et al (2008) High prevalence of central adrenal insufficiency in patients with Prader–Willi syndrome. J Clin Endocrinol Metab 93:1649–1654.
Eiholzer U, Stutz K, Weinmann C, et al (1998) Low insulin, IGF-I and IGFBP-3 levels in children with Prader–Labhart–Willi syndrome. Eur J Pediatr 157:890–893.
Eiholzer U, Gisin R, Weinmann C, et al (1998) Treatment with human growth hormone in patients with Prader-Labhart–Willi syndrome reduces body fat and increases muscle mass and physical performance. Eur J Pediatr 157:368–377.
Englander MT, Dulawa SC, Bhansali P, et al (2005) How stress and fluoxetine modulate serotonin 2C receptor pre-mRNA editing. J Neurosci 25:648–651.
Filipowicz W, Pogacic V (2002) Biogenesis of small nucleolar ribonucleoproteins. Curr Opin Cell Biol 14:319–327.
Fitzgerald LW, Iyer G, Conklin DS, et al (1999) Messenger RNA editing of the human serotonin 5-HT2C receptor. Neuropsychopharmacology 21:82 S–90 S.
Flomen R, Knight J, Sham P, et al (2004) Evidence that RNA editing modulates splice site selection in the 5-HT2C receptor gene. Nucleic Acids Res 32:2113–2122.
Hackler EA, Airey DC, Shannon CC, et al (2006) 5-HT(2C) receptor RNA editing in the amygdala of C57BL/6 J, DBA/2 J, and BALB/cJ mice. Neurosci Res 55:96–104.
Hanamura A, Caceres JF, Mayeda A, et al (1998) Regulated tissue-specific expression of antagonistic pre-mRNA splicing factors. RNA 4:430–444.
Hertel KJ (2008) Combinatorial control of exon recognition. J Biol Chem 283:1211–1215.
Jepson JE, Reenan RA (2008) RNA editing in regulating gene expression in the brain. Biochim Biophys Acta 1779:459–470.
Jurica MS, Moore MJ (2003) Pre-mRNA splicing: awash in a sea of proteins. Mol Cell 12:5–14.
Kawahara Y, Grimberg A, Teegarden S, et al (2008) Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of fat mass. J Neurosci 28:12834–12844.
Kishore S, Stamm S (2006) The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. Science 311:230–232.
Kishore S, Stamm S (2006) Regulation of alternative splicing by snoRNAs. Cold Spring Harb Symp Quant Biol LXXI:329–334
Kishore S, Khanna A, Zhang Z, et al (2010) The snoRNA MBII-52 (SNORD 115) is processed into smaller RNAs and regulates alternative splicing. Hum Mol Genet 19:1153–1164.
Liu S, Li P, Dybkov O, et al (2007) Binding of the human Prp31 Nop domain to a composite RNA-protein platform in U4 snRNP. Science 316:115–120.
Maniatis T, Tasic B (2002) Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature 418:236–243.
Matera AG, Terns RM, Terns MP (2007) Non-coding RNAs: lessons from the small nuclear and small nucleolar RNAs. Nat Rev Mol Cell Biol 8:209–220.
Mehler MF, Mattick JS (2007) Noncoding RNAs and RNA editing in brain development, functional diversification, and neurological disease. Physiol Rev 87:799–823.
Morabito MV, Abbas AI, Hood JL, et al (2010) Mice with altered serotonin 2C receptor RNA editing display characteristics of Prader-Willi Syndrome. Neurobiol Dis 39:169–180.
Nahkuri S, Taft RJ, Korbie DJ, et al (2008) Molecular evolution of the HBII-52 snoRNA cluster. J Mol Biol 381:810–815.
Neu-Yilik G, Kulozik AE (2008) NMD: multitasking between mRNA surveillance and modulation of gene expression. Adv Genet 62:185–243.
Nishikura K (2006) Editor meets silencer: crosstalk between RNA editing and RNA interference. Nat Rev Mol Cell Biol 7:919–931.
Niswender CM, Copeland SC, Herrick-Davis K, et al (1999) RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem 274:9472–9478.
Pan Q, Shai O, Lee LJ, et al (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40:1413–1415.
Robberson BL, Cote GJ, Berget SM (1990) Exon definition may facilitate splice site selection in RNAs with multiple exons. Mol Cell Biol 10:84–94.
Rogelj B, Hartmann CE, Yeo CH, et al (2003) Contextual fear conditioning regulates the expression of brain-specific small nucleolar RNAs in hippocampus. Eur J Neurosci 18:3089–3096.
Runte M, Huttenhofer A, Gross S, et al (2001) The IC-SNURF-SNRPN transcript serves as a host for multiple small nucleolar RNA species and as an antisense RNA for UBE3A. Hum Mol Genet 10:2687–2700.
Sahoo T, del Gaudio D, German JR, et al (2008) Prader–Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster. Nat Genet 40:719–721.
Scott MS, Avolio F, Ono M, et al (2009) Human miRNA precursors with box H/ACA snoRNA features. PLoS Comput Biol 5:e1000507.
Sharp PA (1994) Split genes and RNA splicing. Cell 77:805–815.
Shin C, Manley JL (2004) Cell signalling and the control of pre-mRNA splicing. Nat Rev Mol Cell Biol 5:727–738.
Smith CW, Valcarcel J (2000) Alternative pre-mRNA splicing: the logic of combinatorial control. Trends Biochem Sci 25:381–388.
Stamm S (2002) Signals and their transduction pathways regulating alternative splicing: a new dimension of the human genome. Hum Mol Genet 11:2409–2416.
Stamm S (2008) Regulation of alternative splicing by reversible phosphorylation. J Biol Chem 283:1223–1227.
Stamm S, Riethoven JJ, Le Texier V, et al (2006) ASD: a bioinformatics resource on alternative splicing. Nucleic Acids Res 34:D46–D55.
Stark H, Luhrmann R (2006) Cryo-electron microscopy of spliceosomal components. Annu Rev Biophys Biomol Struct 35:435–457.
Steitz JA, Tycowski KT (1995) Small RNA chaperones for ribosome biogenesis. Science 270:1626–1627.
Stoss O, Stoilov P, Hartmann AM, et al (1999) The in vivo minigene approach to analyze tissue-specific splicing. Brain Res Prot 4:383–394.
Taft RJ, Glazov EA, Lassmann T, et al (2009) Small RNAs derived from snoRNAs. Rna 15:1233–1240.
Tang Y, Novoyatleva T, Benderska N, et al (2005) Analysis of Alternative Splicing In Vivo using Minigenes. In: Westhof E, Bindereif A, Schön A, Hartmann E, eds. Handbook of RNA Biochemistry. Weinheim: Wiley-VCH, pp. 755–782.
Thanaraj TA, Clark F (2001) Human GC-AG alternative intron isoforms with weak donor sites show enhanced consensus at acceptor exon positions. Nucleic Acids Res 29:2581–2593.
Thanaraj TA, Stamm S (2003) Prediction and statistical analysis of alternatively spliced exons. Prog Mol Sub Biol 31:1–31.
Vickers SP, Dourish CT, Kennett GA (2001) Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology 41:200–209.
Wahl MC, Will CL, Luhrmann R (2009) The spliceosome: design principles of a dynamic RNP machine. Cell 136:701–718.
Wang Q, O’Brien PJ., Chen C-X, et al (2000) Altered G protein-coupling functions of RNA editing isoform and splicing variant serotonin 2C receptors. J Neurochem 74:1290–1300.
Wang ET, Sandberg R, Luo S, et al (2008) Alternative isoform regulation in human tissue transcriptomes. Nature 456:470–476.
Werry TD, Loiacono R, Sexton PM, et al (2008) RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function. Pharmacol Ther 119:7–23.
Xu Y, Jones JE, Kohno D, et al (2008) 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron 60:582–589.
Acknowledgments
The laboratory is supported by the Deutsche Forschungsgemeinschaft (DFG), the European Union (EURASNET), and the NIH.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Kishore, S., Stamm, S. (2011). Role of Alternative Splicing of the 5-HT2C Receptor in the Prader–Willi Syndrome. In: Di Giovanni, G., Esposito, E., Di Matteo, V. (eds) 5-HT2C Receptors in the Pathophysiology of CNS Disease. The Receptors, vol 22. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-941-3_21
Download citation
DOI: https://doi.org/10.1007/978-1-60761-941-3_21
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-940-6
Online ISBN: 978-1-60761-941-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)